secwatch.observer — SEC 8-K summary
======================================

Issuer:     Renalytix plc (RNLXY)
CIK:        0001811115
Form:       8-K
Filed at:   2024-05-15T23:59:59+00:00
Accession:  0000950170-24-060026
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Renalytix Q3 revenue $0.5M; net loss $7.7M; strategic sale process initiated
----------------------------------------------------------------------------

- Revenue of $0.5M, down from $0.7M YoY; net loss narrowed to $7.7M from $12.1M.
- Cash and equivalents $4.7M; operating cash burn $4.9M, down ~40% from prior quarter.
- Total test volume 806 (82% billable); primary care orders up 33% QoQ.
- Strategic sale process initiated with multiple potential acquirers in discussions.
- FDA-authorized kidneyintelX.dkd launched April 2024; Medicare coverage draft issued.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1811115/000095017024060026/0000950170-24-060026-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1811115/000095017024060026/rnlx-20240515.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-060026

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer